Q1 2023

Filed May 15, 2023 · 10-Q · 45 days after period end · 0001493152-23-017492

Q1 2023 · 10-Q

Revenue—

Net Income

-$227.00K

N/M vs Q1 2022

EPS Diluted

-$0.21

no prior Q1 2022 on file

Operating Income-$3,665,000N/M

Operating Cash Flow-$2,906,000N/M

Same quarter

Metric	Q1 2023	Q1 2022	Q1 2021	Q1 2020
Revenue	—	—	$0.00	$0.00
Net Income	-$227.00K	-$5.44M	-$29.68M	-$1.71M
EPS Diluted	-$0.21	—	-$1.83	-$0.02

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR